Loading…
Employees: 2,088
Size SMS Pharmaceuticals (SMSPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $495M, the 846th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹498.55 on 6 Nov 2026.
Performance Over six months the shares gained 18.3%, against -18.1% for the median peer and 0.0% for the India market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 10.2% over the last twelve months (peer median -0.4%); the operating margin is 14.8% (peer median -4.1%).
Valuation It trades at 44.1× forward earnings against a peer median of 10.8× (most expensive of 5).
Capital Return on invested capital runs 1.9 points below its cost of capital (14.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹8.98B | ₹8.83B | ₹7.79B | ₹7.06B | ₹5.20B |
| Revenue growth | — | +13% | +10% | +36% | — |
| Gross profit | ₹1.75B | ₹1.84B | ₹1.53B | ₹1.20B | ₹478M |
| EBITDA | ₹1.73B | ₹1.68B | ₹1.38B | ₹1.15B | ₹535M |
| Net income | ₹1.02B | ₹1.02B | ₹691M | ₹498M | -₹70.6M |
| Free cash flow | n/a | -₹926M | -₹589M | -₹236M | -₹282M |
| Capital expenditure | n/a | ₹1.31B | ₹1.23B | ₹522M | ₹299M |
| Total debt | n/a | ₹3.65B | ₹3.11B | ₹2.81B | ₹2.54B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SMSPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.3% | -9.6% | 2nd highest of 21 |
| 6-month return | +18.3% | -18.1% | 4th highest of 20 |
| Distance from 52-week high | -6.8% | -42.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +10.2% | -0.4% | 8th highest of 19 |
| Operating margin | 14.8% | -4.1% | 3rd highest of 19 |
| Forward P/E | 44.1× | 10.8× | most expensive of 5 |
| ROIC minus cost of capital | -1.9 pp | -5.4 pp | 8th highest of 17 |
| EV / EBITDA | 27.1× | 6.1× | most expensive of 4 |
| Net debt / EBITDA | 1.9× | -1.2× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 44.1× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | n/a | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 14.3× | 1.7% | +14.5% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | n/a | -2.6% | -5.6% |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | n/a | 47.1% | -12.3% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | n/a | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | n/a | n/a | n/a |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 4.1× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 7.2× | -18.6% | +6.3% |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | n/a | 13.4% | +1.4% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | n/a | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | n/a | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | n/a | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | n/a | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 21.0× | 5.7% | +3.3% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | n/a | -4.9% | +0.7% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | n/a | 6.7% | -4.1% |